Cite
HARVARD Citation
Pozniak, A. et al. (2017). Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. HIV clinical trials. 18 (4), pp. 141-148. [Online].